ASP7657

synthesized selective E-type prostaglandin (EP)4 receptor antagonist

Also Known As:

trans-4-((((1-(quinolin-2-ylmethyl)-5-(trifluoromethyl)-1H-indol-7 yl) carbonyl) amino) methyl) cyclohexanecarboxylic acid methanesulfonate

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Chronic Renal Insufficiency 01/01/2019 - "We investigated the renoprotective properties of the novel PGE2 EP4 receptor-selective antagonist ASP7657 in 5/6 nephrectomized rats, a chronic kidney disease (CKD) model. " 01/01/2019 - "Renoprotective effects of the novel prostaglandin EP4 receptor-selective antagonist ASP7657 in 5/6 nephrectomized chronic kidney disease rats."
2.	Chronic Kidney Failure (Chronic Renal Failure) 01/01/2019 - "These results suggest that ASP7657 suppresses the progression of chronic renal failure by modulating renin release and improving renal hemodynamics, and may therefore be a promising therapeutic option for inhibiting the progression of CKD."
3.	Fibrosis (Cirrhosis) 01/01/2019 - "Eight weeks of repeated administration of ASP7657 (0.001-0.1 mg/kg) dose-dependently and significantly reduced urinary protein excretion and attenuated the development of glomerulosclerosis and tubulointerstitial damage, including fibrosis and inflammatory cell infiltration, without affecting blood pressure. "
4.	Albuminuria 12/01/2018 - "In addition, 4 weeks repeated oral administration of ASP7657 dose-dependently attenuated albuminuria in type 2 diabetic mice; these effects were significant at doses of 0.01 mg/kg or higher. "

1.	EP4 Subtype Prostaglandin E Receptors
2.	Dinoprostone (PGE2)
3.	Renin
4.	Proteins (Proteins, Gene)

1.	Oral Administration